fg-4592 has been researched along with Myelodysplastic-Syndromes* in 4 studies
1 review(s) available for fg-4592 and Myelodysplastic-Syndromes
Article | Year |
---|---|
Clinical and Molecular Insights in Erythropoiesis Regulation of Signal Transduction Pathways in Myelodysplastic Syndromes and β-Thalassemia.
Erythropoiesis regulation is essential in normal physiology and pathology, particularly in myelodysplastic syndromes (MDS) and β-thalassemia. Several signaling transduction processes, including those regulated by inositides, are implicated in erythropoiesis, and the latest MDS or β-thalassemia preclinical and clinical studies are now based on their regulation. Among others, the main pathways involved are those regulated by transforming growth factor (TGF)-β, which negatively regulates erythrocyte differentiation and maturation, and erythropoietin (EPO), which acts on the early-stage erythropoiesis. Also small mother against decapentaplegic (SMAD) signaling molecules play a role in pathology, and activin receptor ligand traps are being investigated for future clinical applications. Even inositide-dependent signaling, which is important in the regulation of cell proliferation and differentiation, is specifically associated with erythropoiesis, with phospholipase C (PLC) and phosphatidylinositol 3-kinase (PI3K) as key players that are becoming increasingly important as new promising therapeutic targets. Additionally, Roxadustat, a new erythropoiesis stimulating agent targeting hypoxia inducible factor (HIF), is under clinical development. Here, we review the role and function of the above-mentioned signaling pathways, and we describe the state of the art and new perspectives of erythropoiesis regulation in MDS and β-thalassemia. Topics: Animals; beta-Thalassemia; Cell Differentiation; Cell Proliferation; Clinical Trials as Topic; Erythropoiesis; Erythropoietin; Glycine; Hematinics; Humans; Hypoxia-Inducible Factor 1; Isoquinolines; Ligands; Mice; Myelodysplastic Syndromes; Phosphatidylinositol 3-Kinases; Signal Transduction; Smad Proteins; Transforming Growth Factor beta; Type C Phospholipases | 2021 |
1 trial(s) available for fg-4592 and Myelodysplastic-Syndromes
Article | Year |
---|---|
Roxadustat for the treatment of anemia in patients with lower-risk myelodysplastic syndrome: Open-label, dose-selection, lead-in stage of a phase 3 study.
Anemia is the predominant cytopenia in myelodysplastic syndromes (MDS) and treatment options are limited. Roxadustat is a hypoxia-inducible factor prolyl hydroxylase inhibitor approved for the treatment of anemia of chronic kidney disease in the UK, EU, China, Japan, South Korea, and Chile. MATTERHORN is a phase 3, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of roxadustat in anemia of lower risk-MDS. Eligible patients had baseline serum erythropoietin ≤ 400 mIU/mL, and a low packed RBC transfusion burden. In this open-label (OL), dose-selection, lead-in phase, enrolled patients were assigned to 1 of 3 roxadustat starting doses (n = 8 each): 1.5, 2.0, and 2.5 mg/kg. The primary efficacy endpoint of the OL phase was the proportion of patients with transfusion independence (TI) for ≥ 8 consecutive weeks in the first 28 treatment weeks. A secondary efficacy endpoint was the proportion of patients with a ≥ 50% reduction in RBC transfusions over an 8-week period compared with baseline. Adverse events were monitored. Patients were followed for 52 weeks. Of the 24 treated patients, TI was achieved in 9 patients (37.5%) at 28 and 52 weeks; 7 of these patients were receiving 2.5 mg/kg dose when TI was achieved. A ≥ 50% reduction in RBC transfusions was achieved in 54.2% and 58.3% of patients at 28 and 52 weeks, respectively. Oral roxadustat dosed thrice weekly was well tolerated. There were no fatalities or progression to acute myeloid leukemia. Based on these outcomes, 2.5 mg/kg was the chosen starting roxadustat dose for the ongoing double-blind study phase. Topics: Aged; Anemia; Double-Blind Method; Female; Glycine; Humans; Isoquinolines; Male; Middle Aged; Myelodysplastic Syndromes; Placebo Effect; Treatment Outcome | 2022 |
2 other study(ies) available for fg-4592 and Myelodysplastic-Syndromes
Article | Year |
---|---|
Targeting ineffective hematopoiesis in myelodysplastic syndromes.
Topics: Aged; Anemia; Blood Transfusion; Disease Management; Female; Glycine; Hematinics; Hematopoiesis; Humans; Isoquinolines; Myelodysplastic Syndromes; Signal Transduction | 2022 |
New Approaches for Anemia in MDS.
Topics: Activin Receptors, Type II; Anemia; Female; Glycine; Humans; Immunoglobulin Fc Fragments; Isoquinolines; Myelodysplastic Syndromes; Oligonucleotides; Recombinant Fusion Proteins | 2020 |